InnoCare and Keymed Approved to Start Trials of CD20xCD3 Bispecific

Beijing InnoCare and Chengdu 's Keymed announced their IND for a CD20xCD3 bispecific antibody was cleared in China . CM355 binds to CD20 on tumor cells and CD3 on T cells using T-cell Directed Cellular Cytotoxicity (TDCC) to treat CD20+ B-cell malignancies. Non-Hodgkin lymphomas make up 80%-90% of all CD20+ B-cell malignancies. A joint venture formed by the two companies, Tiannuojiancheng Pharma, developed the bispecific. More details.... Stock Symbols: (HK: 09969) (HK: 02162) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.